Codiak Biosciences

company

About

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.

  • 101 - 250

Details

Last Funding Type
Series B
Last Funding Money Raised
$61M
Industries
Biotechnology,Medical,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
101 - 250
Operating Status
Active

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$168.50M
Codiak Biosciences has raised a total of $168.50M in funding over 2 rounds. Their latest funding was raised on Nov 29, 2017 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 29, 2017 Series C $76.50M 1 Detail
Jan 26, 2016 Series B $61M 1 ARCH Venture Partners Detail
Nov 17, 2015 Series A $31M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Codiak Biosciences is funded by 1 investors. ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series C